A8STRACT. Schonlein-Henoch purpura (SHP) is an acute immune-mediated vasculitis characterized by infiltration of polymorphonuclear leukocytes into the vessel wall causing damage to the vascular endothelium by the release of proteolytic enzymes. The local inflammatory and thrombotic process may be regulated by increased biosynthesis of vasoacti ve prostanoids. We investigated the biosynthesis of thromboxane A z (TxA z ), a potent vasoconstrictor and platelet agonist, prostacyclin (PGI z ), a vasodilator and platelet antagonist, and prostaglandin E z , a mediator of inflammation, in 14 children with SHP by physicochemical analysis of index metabolites in plasma and urine. TxA z and PGI2 biosynthesis in the systemic circulation was significantly elevated in the acute phase of the disease and correlated with the degree of clinical symptom s. Recurrent episodes of the disea se were associated with phasic increa ses of plasma and urinary TxA z and PGI z metabolites. Renal TxA 2 formation was highest in two patients presenting with the nephrotic syndrome and extracapillary glomerulonephritis. Pro staglandin E z biosynthesis in the systemic circulation was increased in the acute phase of the disea se. The enhanced TxAz formation is consistent with phasic platelet activation in SHP. The increased PGIz biosynthesis reflects endothelial cell damage and may be a response of vascular endothelium to modulate plateletvessel wall and leukocyte-vessel wall interactions. Increa sed prostaglandin E, formation, which probably derives from acti vated polymorphonuclear leukoc ytes and macrophages, is thought to be related to the inflammatory process in SHP. (Pediatr Res 32: 137-140, 1992 ) Abbreviations SHP, Schonlein-Henoch purpura SHP is the most com mon form of vasculitis in child ren (1). The vasculitis is initiated by the subendothelial deposition of IgA/IgG im m une complexes in small blood vessels (2). Complement activation induces infiltratio n of polym orph onuclear leukocytes, which by th e release of prot eolytic enzym es cause damage to th e vessel wall with secondary th rombosis and hem orrhage (3). Th e altered integrity of the vascular endothelium is likely to involve changes in prostanoid biosynthesis at the platelet vascular interface. Tx A 2 , the major cyclooxygenase product of ara chidonic acid in platelets, is a pot ent platelet aggregator and vasocon strictor (4). Th e potential pathophy siologic role of TxA 2 in acute immune-mediated vasculitic disorders has not yet been elucidated.
SHP is the most com mon form of vasculitis in child ren (1). The vasculitis is initiated by the subendothelial deposition of IgA/IgG im m une complexes in small blood vessels (2) . Complement activation induces infiltratio n of polym orph onuclear leukocytes, which by th e release of prot eolytic enzym es cause damage to th e vessel wall with secondary th rombosis and hem orrhage (3) . Th e altered integrity of the vascular endothelium is likely to involve changes in prostanoid biosynthesis at the platelet vascular interface. Tx A 2 , the major cyclooxygenase product of ara chidonic acid in platelets, is a pot ent platelet aggregator and vasocon strictor (4) . Th e potential pathophy siologic role of TxA 2 in acute immune-mediated vasculitic disorders has not yet been elucidated.
In the present study, we investigated TxA z biosynthesis in childr en with SHP pros pectively during the disease process. To avoid sam pling and analytical probl em s, T xA z biosynthesis was examined by a highly specific and sensitive method, which measures two m ajor urinary enzymatic metabolites, I I-dehydroTx8 2 an d 2,3-dino r-TxB2, which are index metabolites of TxA 2 acti vatio n in th e systemic circulatio n (5, 6) , and by measuri ng urin ary Tx B 2 , which predominantly reflects renal TxA 2 form ation (7) . In addition , circulating Tx A 2 levels were estim ated by determination of plasma II-dehydro-TxB 2 , the mos t abundant enzymatic metabolite of TxB2 (6, 8) .
An oth er prostanoid th at may modulate the fun ction of the altered endo thelium in SHP is PG Iz, the major cyclooxygena se prod uct of arachido nic acid in vascular endo thelium, with potent vasodi lative and antiaggregatory properties (9) . PG Iz biosynthesis was assessed by use of a highly specific, noninvasive meth od . Th is is th e measu rem ent of its urin ary metab olite 2,3-dinor-6-keto-PGFla as an index of systemic PGl 2 formation ( 10) an d measurem ent of 6-keto -PGF . a, which is derived pred om inantl y from the kidn ey (7) . In parallel, the biosynthesis of PGE2, a putative mediator of inflam mation with vasodilative and permeability increasing properties (11), was exam ined by measuring its urinary metabolite, PGE-M, as an ind ex metabolite of systemic PG E 2 activity (12).
M AT ERI ALS AND M ET HO DS
Patients and study design. Fourteen children (four girls and 10 boys), aged 2.5 to 16 (m edian 6) y, were studied. All had th e typical cuta neous man ifestation s of SHP and joint sympto ms; eight pat ient s had gastro intestinal involvement and seven patients had renal involve me nt with microh ematuria and proteinuri a. Two pat ients developed the neph rot ic syndrome with impaired renal fun ction . In the latt er two patients, renal biopsy showed diffuse extracapillary glom erul onephritis with 100 % cellular crescents and endo/extracapillary glom erulonephritis with 100% cellular crescent s, respectiv ely. By immunofluorescence , both biopsies contained granular deposits of IgA in the glomerular mesangium .
Patients who had taken aspirin or other cycloo xygenase inhi b-
itors in the preceding 10 d were excluded. Patients were prospectively assessed by their attending physicians according to a clinical score (Table I) to quantitate the severity of their extrarenal organ involvement. Patients with a clinical score> 2 (algebraic sum of the three organ involvements) were assigned to the acute phase; the recovery phase was defined as the absence of any extrarenal symptoms of SHP (clinical score = 0). On admission, blood was obtained for determination ofplasma l l-dehydro-Txls-, Subsequent blood samples were taken serially every 3rd day. Simultaneously, urine was collected during 24 h from admi ssion until discharge from the hospital. Total urine output was determined and aliquots were stored at -80·C for anal ysis of prostanoids. To examine the association between clinical activity and prost anoid activit y, the severity of clinical involvement was quantified by a score related to skin, joint, and intestinal manifestations ( Table I ). The plasma and urine samples obtained in the presence of most severe clinical symptoms (i. e. with the highest algebraic sum of the three extrarenal organ involvements) were compared with those obtained in the recovery phase and with controls ( 12 age-and sex-matched health y children). Informed consent was obtained from each child' s parent(s) before entry into the stud y. Th e protocol was approved by the Ethics Committee of the University of Heidelb erg.
Analytical methods. For the anal ysis of urinary and plasma prostanoids, gas chromatographic mass spectrometric methods were used, which have been described previously (13) . Following the principle of stable isotope assays, endogenous prostanoids were quantitated against their respective deuterated analogues, which were added as internal standards at the beginning of the procedure. The determination of 6-keto-PGF l a involved extraction by octadecyl silica and normal phase silica cartridges, purification by HPLC, derivatization to the meth ylester-methoximetrimethylsilylethers , and quantitation by capillary gas chromatography mass spectrometry in the electron impact mode (13). The 2,3-dinor-6-keto-PGF l a was purified by extraction and back extraction under alkaline and acidic conditions and thin-layer chromatography. The pentafluorobenzylester-methoxime-trimethylsilyether deri vative was anal yzed by gas chromatography mass spectrometry in the negative ion chemical ionization mode (13) . The 2,3-dinor-TxB 2 and TxB 2 were extracted chemoselectively by phenylboronic acid columns, purified by thin-layer chromatography, derivatized, and quantitated in analogy to 2,3-dinor-o-keto-Pfif'i, (13) . The l l-dehydro-Txls-was extra cted from plasma and urine by octadecyl silica cartridges, purified by thin-layer chromatography, and anal yzed as the pentafluorobenzylester-trimethylsilylether by gas chromatography-tandem mass spectrometry as described previousl y (6). PGE-M was extracted as the methoxime by eth yl acetate/hexane, derivated to the pentafluorobenzylester, purified by thin-layer chromatography, the trimethylsilylether was formed , and PGE-M was quantified by gas chromatography-tandem mass spectrometry. Anal yses of creatinine in serum and urine were performed by routine laboratory methods.
Prostanoid excretion rates were expressed as ng/h/1.73 m 2 calculated per 100 mL glomerular filtrat ion rate (creatinine clearance) to correct for th e influence of different degrees of Plasma levels of l l-d ehydro-Txb, and peak urinary excretion rates of l l-dehydro-Txls , and 2,3-dinor-Tx B 2 were significantly elevated in the acute phase of SHP compared to the recovery phase and to the control group ( Table 2) . Excretion of 11-dehydro-TxB, was almost twice that of 2,3-dinor-TxB 2 in the acute phase and dropped in parallel in the recovery phase to reach similar values as in controls. Urinary Ll-dehydro-Txls, and 2,3-dinor-TxB2 excretion were correlated (r = 0.57; p < 0.00 I). TxB2 excretion was increased in the acute phase , but in contrast to the index metabolites of systemic Tx activit y it did not significantl y differ between acut e and recovery phase (Table  2 ). However, there was a persistently high TxB 2 excretion in the recovery phase of the two patients with nephrotic syndrome and histologically pro ven glomerulonephritis (20.9 and 28.5 ng/h/ 1.73 rrr' ) compared to that of the oth er 12 patients (median 10.2; range 4.9-19.8 ng/h/1.73 m/).
Concomitant with the enhanced systemic TxA 2 formation, PGh biosynthesis was increased in the acute phase as assessed by the urinary excretion rate of 2,3-dinor-6-keto-PGF l a ( Table  2) . This was significantl y correlated with l l-dehydro-Txls, ( r = 0.72; p < 0.001) and 2,3-dinor-TxB2 (r = 0.56; p < 0.005) in the acute phase. In contrast, urinary excretion of 6-keto-PGF l a in the acute phase did not differ significantly from that in the recovery phase and from controls. A significant correlation was found between the algebraic sum of the clinical scores and plasma l l-d ehydro-Txls, (r = 0.54; p < 0.01), urinary l l-d ehydro-Txls, ( r = 0.69; p < 0.0001) (Fig. 1) , urin ary 2,3-dinor-TxB 2 ( r = 0.62 ; p < 0.001), and 2,3-dinor-6-keto-PGF l a (r = 0.64 ; p < 0.0005).
PGE-M excretion rates in the acut e phase were significantly higher (p < 0.01) than during recovery (Table 2) .
DISCUSSI ON
Th is stud y dem onstrates increased systemic TxA 2 formation in the acute phase of patients with SHP that normalizes during recovery from the disease. TxA2 biosynthesis was assessed by specific measurement of indexes of the two major pathways of TxA2 metabolism in the systemic circulation, l l-dehydro-TxB 2 and 2,3-dinor-TxB 2 ( 15, 16) .
The measurement of urinary metabolites has the advantage of being noninvasive and representing time-integrated indexes of TxA 2 biosynthesis (17). As in healthy controls (6) and in conditions with increased platelet-vessel wall interaction (14, 15) , the end ogenous urinary l l-dehydro-TxB 2 excretion rates exceeded tho se of endogenous urina ry 2,3-dinor-TxB2 in the patients with SHP indicating that l l -deh ydro-Txli -is the more abundant urin ary TxA2 metabolite. The combined anal ysis of both the 2,3-dinor and the ll-dehydro metabolites permits us to rule out that incre ased excretion of one metabolite reflects ju st a shift in the metabolic disposit ion of TxA2 and not a true inc reased TxA2 biosynthe sis. The high plasma concentration of the major enzymatic metabolite of TxA 2 , l l-dehydro-TxB 2 , in the acute phase supports our hypothesis of an exaggerated TxA 2 synthesis in SHP.
Because thrombocytes are the major source of TxA, in humans (4), the increased TxA 2 formation can be attributed primarily to platelet activation. Vascular endothelium and macrophages ma y contribute to a small extent to enhanced TxA 2 format ion. In an Clinical score animal model of immune complex vasculitis, platelet accumulation was demonstrated at skin sites in reversed passive Arthus reactions (18) , supporting the concept that increased TxA z formation reflects platelet activation in SHP representing a model of immune complex vasculitis in humans. The close temporal relation between clinical activity and systemic TxA z formation (Fig. I) indicates phasic platelet activation during episodes of active disease. Other methods to investigate platelet function, such as measurement of ,6-thromboglobulin and platelet factor 4, were not obtained in this study because of technical factors stimulating platelet activation artifactually during blood sampling, especially in young children.
Renal Txls, formation was investigated in our study by measuring the urinary excretion rates of the TxAz hydration product TxBz. This predominantly reflects renal TxA z activity when concomitant extrarenal TxA2 stimulation is excluded (7) . It is of interest that renal TxA 2 excretion was higher in two patients with glomerulonephritis and nephrotic syndrome compared to the other cases. It is noteworthy that patients with lupus nephritis, another form of renal vasculitis, present increased urinary TxB z excretion, which correlates with the degree of glomerular injury (19) . Pharmacologic intervention with a selective TxA z antagonist significantly improved renal function in this situation (20) . Accordingly, the investigation of renal TxA 2 formation in patients with SHP nephritis should be pursued.
In addition to an increased TxAz formation, the present study demonstrates enhanced PGlz formation in patients with SHP . This prostanoid is the principal metabolite of arachidonic acid produced by vascular endothelium and has potent vasodilator and platelet antiaggregatory effects (9) . Under physiologic conditions, its circulating blood concentration is too low to exert a biologic effect, but platelet-inhibitory concentrations are formed at the site of vessel injury to limit the degree of platelet activation (21) . Because PGlz formation in our patients was positively correlated to TxAz formation, it is possible that increased endothelial PGlz biosynthesis is a response of vascular endothelium to compensate for TxAz-mediated platelet activation and does not merely reflect damage to the endothelium. Endothelial cell PGlz is also thought to influence leukocyte/vessel wall interactions by blocking leukocyte adhesion after stimulation (22) . It has been demonstrated that PGlz synthesis in vascular cells can be induced by platelet activating factor (23) and IL-l (24), which are both stimulated in immune-mediated vascular disorders (25, 26) . Thus, increased PGI z formation in SHP may not only regulate local thrombotic events but also modulate the inflammatory processes.
A previous study has reported decreased PGI 2 stimulating activity ex vivo in children with SHP (27) . In contrast, the present study demonstrates that the in vivo PGI z biosynthesis is increased in the acute phase of SHP. A similar discrepancy between in vivo and ex vivo PGI z production has also been observed in hemolyticuremic syndrome (14) and may be explained by the fact that 140 TONSHOFF ET AL. measurement of ex vivo POI2 stimulating activity, in contra st to POI 2-m etabolite excretion rates, does not reflect the actual biologically effective activity of POh in vivo.
The elevated systemic POE 2 production found in our study, which probably derives from activated polymorphonuclear leukocytes and macrophages, may be related to the inflammatory process observed in SHP. POE 2 is known to be a mediator of inflammation by promoting blood flow in the inflamed region and thus enhancing edema formation and leukocyte infiltration (28) . On the other hand , POE 2 has a local immunosuppressive effect by inhibiting lymphocyte transformation due to mitogen stimulation, antibody production, and lymphokine production. Therefore, it is difficult to assess whether local POE2 production enhances or suppresses the inflammatory process in SHP.
In conclusion, this study demonstrates increased TxA2 and PGh biosynthesis in children with SHP as a model of immunemediated vasculitis consistent with increased platelet-vessel wall and leukocyte-vessel wall interaction in the disease process. Increased TxA 2 and POI 2 formation have been reported in other diseases with increased platelet vessel wall interaction such as severe atherosclerosis (15), unstable coronary heart disease (29), a nd systemic sclerosis with Raynaud's phenomenon (30) as models of chronic degenerative vasculopath y and in hemolyticuremic syndrome (14) as a model of acute toxic vasculopathy. The similarity of these findings suggests that although dama ge to the vascular endothelium may result from a variety of insults the response of the vascular endothelium is rather uniform.
